awmsg logo



eculizumab (Soliris®)


Reference No. 1153

Publication date:
12/08/2015


Appraisal information

eculizumab (Soliris®) 300 mg concentrate for solution for infusion


Company: Alexion Pharma UK Ltd
BNF category: Nutrition and blood
NMG meeting date: Not scheduled
AWMSG meeting date: 11/02/2015
   
   
Submission Type: NICE HST
Status: Recommended
Advice No: Not available
Ministerial ratification: 12/08/2015

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

The National Institute for Health and Care Excellence (NICE) published advice in January 2015 in relation to eculizumab (Soliris®) for the treatment of patients with atypical haemolytic uraemic syndrome (aHUS). At their meeting on 11th February 2015 AWMSG supported the adoption and implementation of this advice within NHS Wales (refer to the minutes of meetings). The Minister for Health and Social Services has subsequently agreed that the NICE HST advice for eculizumab (Soliris®) should be implemented within NHS Wales. A National Clinical Access Policy will be developed by Welsh Health Specialised Services Committee (WHSSC) with the support of clinical experts, patient representatives and other key stakeholders. Refer to the NICE website for full guidance including any specific restrictions on the use of the technology.